Kornimate/medical-research-clean huggingface dataset:
the skin microbiota in skin disease and eczema

Conditions: Skin Disease; Eczema; Eczema Atopic Dermatitis

Summary: background: the skin microbiota influence skin health in several skin diseases and atopic dermatitis (ad). presence of staphylococcus have been associated to a sever course of the disease. objectives: the aim of the study is to investigate the influence of bacteria, and the skin microbiota on the inflammation and skin barrier. moreover, dysbiosis in the microbiota, the inflammation profile, the skin barrier damage will be related to objective and patient oriented measures. importance: knowledge of interactions between host defense, skin barrier and bacterial colonizing skin can facilitate development of new prevention and treatment strategies to control microbial impact in skin diseases and eczema.

the role of the skin microbiome in atopic eczema and other skin diseases remains to be investigated. there are reports indicating an association of skin-colonization of staphylococcus aureus (s. aureus) and the severity of the disease. skin colonizing pathogens might be important cofactor for persistence of eczema and other skin diseases, as well as the commensal, non-pathogenic, microflora of the skin might have protective effects. the aim of this research project is to investigate the skin microbiome in patients with eczema and other skin diseases and elucidate the relation to skin barrier impairment and severity of the skin disease. specifically, we will: * determine the skin microbiome and metagenome in skin of patients with eczema and other skin diseases. * straighten out the relationship between the skin microbiome, the skin barrier, contact allergies, quality of life, eczema control and severity in patients with eczema and other skin diseases. * identify biological markers, such as antimicrobial peptides, cytokines and gene-expression profiles in skin, and other factors contributing to the development and persistence of eczema and other skin diseases.

Eligibility criteria:
inclusion criteria: skin diseas, atopic eczema, eczema - exclusion criteria: * inabillity to give informed concent
evaluation of paternal, maternal and obstetric factors leading to the hepatitis b immunization failure in hong kong

Conditions: Hepatitis B Infection

Summary: globally, hepatitis b virus (hbv) infection is the most common form of chronic hepatitis. there are still a lot of uncertainties on how infants acquired hbv leading to the development of chronic hbv infection despite active and passive immunoprophylaxis. the investigators would like to carry out a prospective study to answer the following questions: 1. the paternal, maternal and obstetric factors leading to immunoprophylaxis failure 2. the prevalence of immunoprophylaxis failure in hong kong


Eligibility criteria:
inclusion criteria: * all women age ≥ 18 years * maternal or paternal hepatitis b carrier exclusion criteria: * couples will be excluded if female partners of paternal hepatitis b carrier were occult carrier * plan to deliver in other units
family planning through dairy cooperatives

Conditions: The Study Goal is to Assess the Introduction of Sustainable Family Planning/Reproductive Health Information and Services Through; Land O' Lakes-supported Dairy Cooperatives

Summary: this observational study will assess a model for providing family planning through quarterly events organized by dairy cooperatives supported by land o'lakes in kenya.

access to family planning and other reproductive health services remains difficult in much of rural kenya. one option for improving rural access to family planning is to use existing community events outside of the health sector as platforms for delivering information and services. this study will assess a model for providing family planning through quarterly events organized by dairy cooperatives supported by land o'lakes in kenya. during these events, known as field days, a healthcare provider will have a tent in which field day attendees can receive basic family health services free of charge. the services offered will be: family planning counseling and methods, immunizations, antenatal care, screening and treatment for sexually transmitted infections, and hiv counseling and testing. since the services are no different than those that could be obtained at ministry of health or some private facilities, the service provision is not considered to be part of the research. women receiving any service from the health care provider will be recruited for an interview that will measure their demand for family planning and attitudes about receiving services during the field day. in addition, the study will track the number of different types of services provided, the total number of field day attendees, and the cost of the service model. the study will be carried out at five field days in rift valley and central provinces. participants will not be tested for sti/hiv as part of this research; however, at their request, they may have received a test from the provider prior to the research interview. at the time of consent, they will have already received the test, so the consent form will not include anything specific to testing. in kenya, all sti/hiv test results are reported to the national public health authorities. these reports are not used for contacting patients but for planning purposes.

Eligibility criteria:
inclusion criteria:females aged 18-49 receiving health services at a field day event - exclusion criteria: -

Keywords: ae adverse event aids acquired immunodeficiency syndrome alt (sgpt) alanine aminotransferase art antiretroviral therapy ast (sgot) aspartate aminotransferase dcf data collection forms dmc data monitoring committee fda (u.s.) food and drug administration gcp good clinical practice guidelines hb sag hepatitis b surface antigen ich international conference of harmonisation ind investigational new drug application irb institutional review board iu international units mg milligram(s) mm3 cubic millimeter(s) pcr polymerase chain reaction sae serious adverse event µg microgram uln upper limit of the normal range wb western blot
study of acid peel and laser for the treatment of melasma

Conditions: Melasma

Summary: the objective of this study is to evaluate laser treatment and acid peel for the treatment of melasma.

the purpose of this study is to evaluate the safety and efficacy of laser treatment and acid peel for the treatment of melasma.

Eligibility criteria:
inclusion criteria: * diagnosis of melasma lesion measuring at least 4 square centimeters. * age 18-75 years. * good health. * willingness and ability to understand and provide informed consent for participation in the study. * ability to communicate with the investigator. * must be willing to forgo other treatment options for melasma during the course of the study. exclusion criteria: * inability to understand the protocol or to give informed consent. * mental illness. * under 18 years of age and over 75 years of age. * laser treatment in the last 6 months before enrollment. * isotretinoin within the past year. * lidocaine allergy. * history of herpes simplex viral infection. * concurrent active disease to facial area (i.e acne). * bleeding disorder. * history of abnormal wound healing. * history of abnormal scarring.
masitinib in combination with gemcitabine for treatment of patients with advanced/metastatic pancreatic cancer

Conditions: Pancreatic Cancer

Summary: the objective of this study is to compare the efficacy and safety of masitinib in combination with gemcitabine to placebo in combination with gemcitabine in patients with advanced/metastatic pancreatic cancer.

human pancreatic cancer overexpresses a number of important tyrosine kinase (tk) growth factors receptors and ligands, including expression of both pdgf and pdgf receptors. drugs that can selectively inhibit tks are likely to be of benefit in pancreatic cancer. masitinib is a tk inhibitor, selectively and effectively inhibiting c-kit (mast cell growth factor receptor), pdgf receptor, fgf receptor and to a lower extent the fak kinases. pre-clinical and clinical studies have shown that masitinib can reverse resistance of pancreatic tumor cell lines to gemcitabine. based on pre-clinical and phase 2 clinical studies, masitinib can be considered as a good candidate to use in combination with gemcitabine in the treatment of pancreatic cancer.

Eligibility criteria:
main inclusion criteria: 1. histologically or cytologically confirmed adenocarcinoma of the pancreas 2. chemo naïve patients with advanced/metastatic disease 3. documented decision justifying non eligibility for surgical resection. the documentation of the non eligibility for surgical resection will be reviewed by an independent committee. 4. men and women, age \>18 years 5. men and women of childbearing potential (entering the study after a confirmed menstrual period and who have a negative pregnancy test), must agree to use two methods (one for the patient and one for the partner) of medically acceptable forms of contraception during the study and for 3 months after the last treatment intake. 6. patient should be able and willing to comply with study visits and procedures as per protocol. 7. patient should understand, sign, and date the written voluntary informed consent form at the screening visit prior to any protocol-specific procedures performed. main exclusion criteria: 1. patient treated for a cancer other than pancreatic cancer within 5 years before enrollment, with the exception of basal cell carcinoma or in situ cervical cancer 2. any condition that the physician judges could be detrimental to subjects participating in this study; including any clinically important deviations from normal clinical laboratory values or concurrent medical events previous treatment 3. any anti-tumor therapy (any chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy) within 6 months prior to baseline 4. treatment with any investigational agent within 4 weeks prior to baseline

Keywords: pancreatic cancer advanced pancreatic cancer metastatic pancreatic cancer gemcitabine chemo-naive
risk factors of bleeding under veno arterial membrane oxygenation

Conditions: Extracorporeal Membrane Oxygenation; Bleeding; Complication

Summary: veno arterial extracorporeal membrane oxygenation (va ecmo) is used, for cardiogenic shock, refractory cardiac arrest and post cardiotomy cardiac failure. bleeding is frequent complications during va ecmo and is associated with increased mortality. the aim of our study was to identify early factors associated with major bleeding in patients supported by va ecmo


Eligibility criteria:
inclusion criteria: patients over 18 years treated by peripheral veno arterial membrane oxygenation exclusion criteria: none
dry needling and high intensity laser therapy in treatment of myofascial pain syndrome

Conditions: Myofascial Pain Syndrome

Summary: 108 myofascial pain syndrome (mps) diagnosed patients will be randomly divided into 3 groups. to groups; exercise, exercise+high-intensity laser therapy (hilt) and exercise+dry needling will be applied. visual anolog scale (vas) scores and neck range of motion (rom) of the patients before-after treatment will be recorded and will be evaluated statistically.

myofascial pain syndrome (mps) is a very common disease in the population that seriously affects the quality of life. although many modalities are used in its treatment, there is still no common protocol. in this study, the investigators aim to compare the effectiveness of high-intensity laser therapy (hilt), which has been popular in recent years, with exercise and dry needling options that have been used for years. in our study 108 myofascial pain syndrome (mps) diagnosed patients will be randomly divided into 3 groups. to groups; exercise, exercise+high-intensity laser therapy (hilt) and exercise+dry needling will be applied. visual anolog scale (vas) scores and neck range of motion (rom) of the patients before-after treatment will be recorded and will be evaluated statistically.

Eligibility criteria:
inclusion criteria: * diagnosed with neck and / or back pain * diagnosed with mps * had a taut band on the trapezius muscle and at least one active trigger point exclusion criteria: * diagnosed with fibromyalgia, * had systemic disease, * significant cervical disc lesion / radiculopathy / myelopathy, * had trigger point injection in the last 6 months, * had neck or shoulder surgery in the year before being included in the study, * was pregnant, * received anticoagulant therapy, * used aspirin in the last three days, and * with the cognitive dysfunction patients

Keywords: myofascial pain syndrome high-intensity laser therapy dry needling exercise
effect of passive ultrasonic irrigation on bacteria that persist after root canal preparation

Conditions: Bacterial Infections

Summary: this study aims to evaluate the effectiveness of ultrasonic irrigation in improving root canal disinfection after chemomechanical procedures.

although chemomechanical procedures promote a drastic bacterial reduction, many root canals remain infected, which points to the need for complementary procedures to improve root canal disinfection. thus, this clinical study aims to evaluate the effect of passive ultrasonic irrigation as a supplementary disinfection procedure after root canal preparation. microbiological samples of the root canals of 30 single-rooted teeth with apical periodontitis will be taken at different stages of the endodontic treatment: before preparation (s1), after chemomechanical procedures (s2) and after passive ultrasonic irrigation (s3). the samples will be submitted to the quantitative polymerase chain reaction for bacterial quantification and to the reverse transcription quantitative polymerase chain reaction for bacterial activity analysis. data will be analyzed using the wilcoxon test for paired samples (p \< 0.05).

Eligibility criteria:
inclusion criteria: * teeth with necrotic pulps and asymptomatic apical periodontitis exclusion criteria: * patients who had received antibiotics during the previous 3 months or had any general disease, * teeth that could not be properly isolated with rubber dam, * non-restored teeth, * periodontal pockets depths greater than 4 mm, * previous endodontic treatment, * open apex, * crown/root fracture * root resorption or calcifications.
safety and tolerability of pod-dhe (inp104) in migraine (stop 301)

Conditions: Migraine Headache

Summary: this study consists of a 4-week screening period, a 24-week treatment period for all participants, followed by a 28-week treatment period extension (to 52 weeks in total) for a subset of at least 60 and up to 80 participants, and a 2-week post-treatment follow-up period.

this is an outpatient study in people who currently suffer a minimum of 2 migraines per month. during the study, participants will be instructed to use no more than 2 doses of the study drug inp104 within a 24-hour period, or 3 doses in a 7-day period. participants will self-administer inp104 nasally and record their migraines in an ediary.

Eligibility criteria:
inclusion criteria: * documented diagnosis of migraine with or without aura, with at least 2 attacks per month for the previous 6 months. * participants must be in good general health, with no significant medical history (excluding migraine). * participants must have the ability and willingness to attend the necessary visits at the study center. * participants must be able to provide the written informed consent prior to entry into the study. * women of childbearing potential must agree to use adequate contraception (as defined in the protocol and by study personnel) during the study and for 30 days after the last dose fo the study drug. * male participants and their partners must agree to use effective contraception (as defined in the protocol and by study personnel) during the study and for 30 days after the last dose of the study drug. male participants should also refrain from sperm donation for 30 days after study completion. exclusion criteria: * subjects with trigeminal autonomic cephalalgias (including cluster headache, hemicrania syndromes and short-lasting unilateral, neuralgiform headache attacks with conjunctival injection and tearing), hemiplegic migraine, or migraine with brainstem aura (previously referred to as basilar migraines). * subjects with chronic migraines, medication overuse headache or other chronic headache syndromes. * subjects with ischemic heart disease or subjects with clinical symptoms or findings consistent with coronary artery vasospasm, including prinzmetal's variant angina. * subjects with significant risk factors for coronary artery disease (cad) including current use of nicotine-containing products, medical history of diabetes, uncontrolled hypertension (high blood pressure), known peripheral arterial disease, raynaud's phenomenon, sepsis or vascular surgery (within 3 months prior to study start), or severely impaired hepatic or renal (kidney) function. * subjects with recurrent sinusitis or epistaxis. * subjects with a history or presence of alcoholism or drug abuse within 2 years prior to first study drug administration. * women who are pregnant, or planning to get pregnant, or who are lactating while participating in the study. * use of any medications prohibited by protocol. * use of \>12 days per month of triptan or ergot-based medication in the 2 months prior to screening. other protocol-defined inclusion/exclusion criteria may apply.
treatment of schizophrenia through internet-based psychoeducation

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: the purpose of this study is to assess the effectiveness of a web-based psychoeducational program in helping people with schizophrenia and their families manage the disease.

this study will provide a comprehensive psychoeducational program which includes education, social support, information, coping strategies, and guidance from mental health, social services, and medical professionals. this study will work to reduce relapse, facilitate patient rehabilitation, decrease family distress, and improve family well being. patients and their families participate in an in-person psychoeducational survival skills workshop that is designed to provide patients and their families with basic information about schizophrenia and its treatment. after the workshop, participants are provided with 6 web-based modules that are designed to increase mental health and schizophrenia knowledge. patient relapse, family distress, family knowledge of schizophrenia, and data on user's acceptance and utilization are measured to determine the intervention's effectiveness.

Eligibility criteria:
inclusion criteria * dsm-iv diagnosis of schizophrenia or schizoaffective disorder * at least 4 hours/week in-person contact with a family member * primary caregiver with a telephone * patient and primary caregiver speak and read english exclusion criteria: * enrolled in another clinical trial * evidence of organic brain syndrome * current alcohol or substance abuse that could explain the presenting index psychotic episode * dsm-iv diagnosis of psychoactive substance dependency
clinical utility of wats3d: a 5-year prospective study

Conditions: Barrett Esophagus; Gastro Esophageal Reflux; Esophageal Dysplasia; Esophageal Diseases

Summary: the purpose of this study is to create a registry (collect data and keep it in a research database) to learn more about two methods of taking small tissue samples from your esophagus (the esophagus is the tube that carries food and liquid from your mouth to your stomach). the two methods of sampling are: 1) using forceps that take biopsies (small tissue samples) from your esophagus, and 2) using a brush that also takes biopsies from your esophagus.

this study will look at the impact of the brush biopsy results on your doctor's decisions about your future care and treatment. in addition , by recording the results of all your biopsies over 5 years, it may be possible to find out if the brush biopsy, forceps biopsy, or both can predict which patients with heartburn develop barrett's esophagus, (an abnormality in the esophagus that may lead to cancer), and which patients with barrett's esophagus develop precancer and cancer. you are being asked to participate in the study because you are receiving an upper endoscopy (a procedure where a tube with a light and camera are inserted in your mouth and down your throat) with forceps and brush biopsies of your esophagus as part of you standard clinical care, and you are at least 18 years old.

Eligibility criteria:
inclusion criteria: * able to read, comprehend and complete the irb-approved consent form * aged 18 or older * meet one of the following: * patients with heartburn or regurgitation undergoing a screening egd, who undergo wats3d sampling and forceps biopsies for suspicion of be, or * patients with known be with or without dysplasia undergoing a surveillance egd with wats3d biopsies and forceps biopsies, or * patients who have undergone endoscopic eradication (i.e. radiofrequency ablation or cryoablation) who are undergoing surveillance egd following the establishment of complete eradication of intestinal metaplasia (ceim) * only patients who undergo both forceps biopsies and wats3d of the esophagus will be included. exclusion criteria: * pregnancy at time of endoscopy * unresolved drug or alcohol dependency that will limit ability to comprehend or follow instructions related to informed consent, post-treatment instructions or follow-up guidelines * medical condition that will likely prohibit completion of a 5 year study
combination study of bms-754807 and herceptin® in patients with advanced or metastatic her-2-positive breast cancer

Conditions: Breast Cancer

Summary: this is a phase i/ii study to evaluate the safety profile, tolerability, pharmacokinetics and pharmacodynamics following daily oral doses of 50 to 200 mg of bms-754807 in combination with trastuzumab (herceptin®) in subjects with advanced or metastatic her-2-positive breast cancer. in addition, the study is expected to identify the recommended dose or dose range of bms-754807 in combination with trastuzumab for phase ii studies and provide preliminary evidence of anti-tumor activity in her-2-positive breast cancer subjects after trastuzumab failure


Eligibility criteria:
for additional information on this trial, please call (910) 558-2913 inclusion criteria: * subjects with locally advanced or metastatic her-2-positive breast cancer who have failed at least one trastuzumab containing regimen. prior treatment with other her-2-targeted agents (e.g. lapatinib, pertuzumab, trastuzumab dm-1 etc.) is allowed * histologic or cytologic diagnosis of her-2-positive breast cancer * ecog status 0 - 1 exclusion criteria: * symptomatic brain metastasis * any condition requiring chronic use of steroids * any disorder with dysregulation of glucose homeostasis (history of type 1 or 2 diabetes mellitus or prediabetic symptoms * history of glucose intolerance * women of child-bearing potential unwilling or unable to use acceptable contraception methods

Keywords: advanced or metastatic her-2-positive breast cancer